Generic Industry Market Forces May Impact GDUFA III Talks
Executive Summary
AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.
You may also be interested in...
Some US Generics May Get To Skip Fed Studies
Office of Generic Drugs official says the FDA may be able to harmonize its requirements with regulators who do not have a blanket mandate.
Some Generics May Get To Skip Fed Study Requirement If US FDA Research Pans Out
Office of Generic Drugs official says the FDA may be able to harmonize its requirements with regulators who do not have a blanket mandate.
New AAM CEO: Traditional Lobbying On Lowering Health Care Costs Can Mix With COVID-19 Talks
Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.